HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
نویسندگان
چکیده
We evaluated HER-2/neu status in 100 consecutive ductal breast carcinomas by using the Food and Drug Administration (FDA) and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) scoring systems. With the FDA system, scores were 3+ in 23.0%, 2+ in 25.0%, and 0 or 1+ in 52.0% of cases. With the ASCO/CAP system, scores were 3+ in 16.0%, 2+ in 34.0%, and 0 or 1+ in 50.0%. With the FDA and ASCO/CAP systems, respectively, 3+ cases (n = 23 and 16, respectively) showed high-grade, granular HER-2/neu amplification in 15 (65%) and 14 (88%); low-grade, borderline amplification in 7 (30%) and 1 (6%); and chromosome 17 polysomy without amplification in 1 (4%) and 1 (6%). Concordance between schemes was higher for cases with high-grade, granular HER-2/neu amplification (concordance coefficient, 0.74). Cases with low-grade, borderline HER-2/neu amplification showed poor concordance (concordance coefficient, 0.20). The FDA and ASCO/CAP schemes for HER-2/neu evaluation select patients differently for trastuzumab therapy. Major discordance is present for low-grade, borderline HER-2/neu amplification. FDA low-grade, borderline tumors would be reclassified as without HER-2/neu amplification or as polysomic. The ASCO/CAP scheme has a great concordance coefficient between strong 3+ immunohistochemical cases and cases with high-grade, granular HER-2/neu amplification.
منابع مشابه
The use of Gold nanorods conjugated with Herceptin in breast cancer treatment by photothermal therapy method in mouse model
Treatment methods for breast cancer are not specific and each one has its own drawbacks. For this reason, scientists are seeking ways in which specifically affect cancer cells. Photothermal therapy is a method that uses near-infrared (NIR) laser energy to create sufficient heat to destroy cancer cells. In this study, the photothermal effect of gold nanorods (GNRs) was investigated for breast ca...
متن کاملThe use of Gold nanorods conjugated with Herceptin in breast cancer treatment by photothermal therapy method in mouse model
Treatment methods for breast cancer are not specific and each one has its own drawbacks. For this reason, scientists are seeking ways in which specifically affect cancer cells. Photothermal therapy is a method that uses near-infrared (NIR) laser energy to create sufficient heat to destroy cancer cells. In this study, the photothermal effect of gold nanorods (GNRs) was investigated for breast ca...
متن کامل3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
Herceptin failure is a major clinical problem in breast cancer. A subset of breast cancer patients with high HER-2/neu levels eventually experience metastatic disease progression when treated with Herceptin as a single agent. Mechanistic details of development of this aggressive disease are not clear. Therefore, there is a dire need to better understand the mechanisms by which drug resistance d...
متن کاملPotential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
BACKGROUND The HER-2/neu oncogene and its p185 receptor protein are indicators of a more aggressive form of breast cancer. HER-2/neu status guides Herceptin therapy, specifically directed to the extracellular domain (ECD) of the HER-2/neu oncoprotein. The HER-2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay. METHODS We performed a systematic review of ...
متن کاملPredicting response to herceptin therapy.
The activation of cellular oncogenes plays an important role in the development of cancer. An important member of the oncogene family is the growth factor receptor known as the human epidermal growth factor receptor-2 (HER-2), which is also referred to as HER-2/neu or c-erbB-2. The HER-2/neu oncogene has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase that is expres...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- American journal of clinical pathology
دوره 129 6 شماره
صفحات -
تاریخ انتشار 2008